Engineered Human Heart Tissue (EHT)
Three-dimensional engineered cardiac muscle strips casting human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and fibroblasts around flexible silicone pillars, measuring auxotonic contractile force, beat frequency, and pro-arrhythmic drug liabilities.
1 · What it gives
Engineered Human Heart Tissue (EHT) defines the forefront of biofabrication and regenerative medicine, constructing patient-specific, three-dimensional, living tissue constructs or implantable biomaterials capable of anatomical restoration and physiological integration. By integrating computer-aided design (CAD/CAM), stimuli-responsive or biofunctional polymer inks, and live-cell extrusion or light-based stereolithography (SLA/DLP), the platform bridges the gap between synthetic biomaterials and native extracellular matrix (ECM). The technology addresses foundational bottlenecks of microvascular perfusability, mechanical mismatch, and cellular ischemia in thick tissue constructs.
The industrial manufacturing train unites medical-grade biomaterial synthesis (such as recombinant humanized collagen, PCL, PLGA, or gelatin-methacryloyl GelMA), multi-axis pneumatic or digital light processing bioprinters, and dynamic perfusion biomimetic bioreactors. In-line stereomicroscopy and optical coherence tomography (OCT) ensure sub-20 um spatial resolution across multi-layered constructs. Fabricated tissue grafts undergo dynamic mechanical conditioning (pulsatile flow, cyclical stretch) to accelerate ECM deposition, maturation, and functional endothelialization before preclinical or clinical transplantation.
The key directions of this technology are:
- Biomimetic Bioink Chemistry & Rheology in Engineered Human Heart Tissue (EHT): Engineering shear-thinning hydrogels with rapid post-extrusion photo-crosslinking (e.g., LAP photoinitiator with 405 nm visible light) to maintain high shape fidelity and >90% cell viability.
- Sacrificial Pluronic / Gelatin Microvascular Channeling: Utilizing thermally reversible sacrificial fugitive inks to pattern interconnected hierarchical vascular networks within centimeter-scale tissue volumes.
- Biomimetic Perfusion Conditioning Bioreactors: Applying physiological pulsatile shear stress and cyclic strain to stimulate smooth muscle and endothelial cell alignment, accelerating vascular graft maturation.
- Biomaterial Biodegradation & Mechanical Mechanics Control: Tailoring polymer molecular weights and crosslinking densities to synchronize scaffold degradation kinetics with native ECM neo-synthesis in vivo.
Sectoral value chain#
┌────────────────────────────────────────────────────────┐
│ Tier 1: Medical-Grade Biomaterial & Bioink Synthesis │
│ (rhCollagen, GelMA, LAP photoinitiator, cell seeding) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 2: Patient Anatomical CAD Modeling & Slicing │
│ (CT/MRI 3D reconstruction, G-code toolpath routing) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 3: Multi-Material Bioprinting & Crosslinking │
│ (Pneumatic extrusion/DLP, visible light photocuring) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 4: Dynamic Perfusion Maturation Bioreactor │
│ (Pulsatile flow, mechanical stretch, endothelization) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 5: Mechanical, Histological & Sterile Release QC │
│ (Tensile burst pressure, suture retention, ISO 10993) │
└────────────────────────────────────────────────────────┘
Value chain levels#
| Level | Description | Key inputs/outputs |
|---|---|---|
| Biomaterial Precursor Synthesis | Precision synthesis and endotoxin purification of clinical-grade bioinks and synthetic polymers. | In: Raw gelatin/PCL, methacrylic anhydride, LAP, WFI. Out: Endotoxin-tested, sterile-filtered bioink components (<0.5 EU/mL). |
| Anatomical Modeling & Toolpath Slicing | Translating patient DICOM volumetric scans into multi-layered toolpaths optimized for printability. | In: Patient CT/MRI imaging data, CAD/CAM slicing software. Out: Validated numerical G-code routines for multi-nozzle bioprinting. |
| Robotic Bioprinting & Photopolymerization | Deposition of living cell-laden inks and structural polymers followed by controlled 405 nm photo-curing. | In: Cell-laden bioink, sacrificial ink, multi-head bioprinter. Out: Structurally coherent, vascularized multi-tissue constructs. |
| Perfusion Bioreactor Tissue Maturation | Culturing constructs under dynamic pulsatile flow and physiological strain to promote native ECM remodeling. | In: Printed constructs, specialized bioreactor chambers, media. Out: Matured living tissue graft with continuous patent lumens. |
| Biomechanical & Biological Release Testing | Comprehensive validation of tensile modulus, suture retention strength, cell viability, and sterility. | In: Mature graft specimens, mechanical testing fixtures. Out: Fully released, clinical-transplantation grade tissue implant. |
Cross-cutting technologies of the sector:
- Optical Coherence Tomography (OCT) Metrology: Real-time non-destructive volumetric scanning verifying internal lumen patency and wall thickness.
- Biaxial Mechanical & Burst Pressure Testing: Ensuring engineered vascular conduits and soft tissues withstand arterial hemodynamic pressures (>1500 mmHg).
2 · What it replaces 3 · matched by industry
3 · How to implement 4 steps
- 1High-purity hiPSC-cardiomyocyte directed differentiationDirecting human iPSCs into >90% cTnT-positive ventricular cardiomyocytes via sequential Wnt signaling modulation.
- 2Parallel hydrogel casting around flexible silicone pillarsEmbedding cell suspensions in collagen-I/fibrin hydrogels within strip-shaped wells containing dual silicone posts.
- 3Mechanical auxotonic conditioning and alignmentAllowing autonomously beating tissues to deflect silicone posts, developing dense anisotropic myofibril sarcomere registration.
- 4Video-optical automated contractility analysisTracking post deflection amplitudes under baseline and inotropic drug challenges to calculate milli-newton contractile forces.
4 · Who delivers
Matched suppliers (matched automatically)
| Esco Aster | Singapore | Services / consulting | active |
| AGC Biologics | United States | Producer | active |
| SynCTI (Singapore) | Singapore | Research / RTO | active |
| De Sangosse | France | Not classified | active |
| Aker BioMarine | Norway | Producer | active |
| ORF Genetics | Iceland | Producer | active |
| Terragia Biofuel Inc. | United States | Producer | active |
| Life3 Biotech | Singapore | Producer | active |
| Hofseth Biocare | Norway | Producer | active |
| CellMEAT | South Korea | Producer | active |
Leading companies and institutes (from the brief)
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| Miltenyi Biotec | 🇩🇪 Germany | CliniMACS Prodigy Automated Processing | Standardized cGMP ATMP bioprocess module and validated analytical release assay suite. | Commercial / Approved |
| Lonza Cell & Gene | 🇨🇭 Switzerland | Cocoon Closed Manufacturing Platform | Standardized cGMP ATMP bioprocess module and validated analytical release assay suite. | Commercial / Approved |
| Cytiva | 🇺🇸 United States | Xuri Cell Expansion Bioreactors & Sefia | Standardized cGMP ATMP bioprocess module and validated analytical release assay suite. | Commercial / Approved |
| WuXi Advanced Therapies | 🇨🇳 China | Viral Vector Testing & Analytical Development | Standardized cGMP ATMP bioprocess module and validated analytical release assay suite. | Commercial / Approved |
| Sartorius Stedim Biotech | 🇩🇪 Germany | Ambr Bioreactors & Process PAT Systems | Standardized cGMP ATMP bioprocess module and validated analytical release assay suite. | Commercial / Approved |
| Thermo Fisher Scientific | 🇺🇸 United States | Gibco CTS Cell Therapy Media | Standardized cGMP ATMP bioprocess module and validated analytical release assay suite. | Commercial / Approved |
5 · Rules & route to market
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States
FDA CDRH/CBER combination product pathways, ARMI BioFab, ISO 10993#
- FDA Combination Product Guidelines: Jurisdictional oversight for Engineered Human Heart Tissue (EHT) navigating drug-device or biologic-device designations between CBER and CDRH.
- ARMI BioFabUSA Manufacturing Consortia: National manufacturing institute standardizing modular automated biofabrication cleanroom systems.
- ISO 10993 Biocompatibility Testing: Rigorous preclinical evaluation of cytotoxicity, genotoxicity, systemic toxicity, and hemocompatibility.
European Union
EU Medical Device Regulation (MDR 2017/745), Swissmedic standards#
- EU MDR Rule 8 / Rule 18 Compliance: Strict conformity assessment for implantable medical devices incorporating tissues or cells of human/animal origin.
- European Bioprinting Hubs: Advanced collaborative research centers across Switzerland (ETH Zürich), Germany (Fraunhofer), and the Netherlands.
- CE Marking Clinical Data Requirements: Comprehensive clinical evaluation reports verifying long-term tissue remodeling and integration safety.
China
NMPA Class III medical device approvals, national 3D printing centers#
- NMPA Priority Review for Innovative Devices: Fast-track clinical review channels for 人源多能干细胞衍生三维工程化跳动心肌组织(EHT,心脏毒性与功能评价) under Class III implantable medical device pathways.
- National Biomanufacturing Centers: State key laboratories in Tsinghua, Zhejiang University, and Shanghai Jiao Tong accelerating clinical translation.
- Regional Medical Device Industrial Parks: High-density clusters in Changzhou, Suzhou, and Shenzhen supplying medical-grade biodegradable polymers.
6 · Money: tenders & grants
| Grant | Continuing Human Enabling Enhancing Restoring and Sustaining Air Force -- Research Lab · United States | Aug 22, 2044 6482 days |
| Grant | First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based … National Institutes of Health · United States | Oct 15, 2027 326 days |
| Grant | Health of ecosystems and wild species, predictions and impacts on human health, in the face of existing and … European Commission · EU | Sep 22, 2027 303 days |
| Grant | Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the … National Institutes of Health · United States | Aug 18, 2027 268 days |
| Grant | NDEP STEM Open NFO Washington Headquarters Services · United States | Feb 8, 2028 442 days |
7 · Tech stack & innovations
- Functional Bioink Formulation in Engineered Human Heart Tissue (EHT):
- Recombinant humanized collagen or modified gelatin matrices with defined methacrylation degrees.
- Non-toxic visible-light photoinitiators (LAP) providing rapid crosslinking under low-intensity 405 nm irradiation.
- High-Precision Multi-Head Biofabrication:
- Pneumatic extrusion printheads coupled with temperature-controlled peltier nozzles.
- Laser-assisted or digital light processing (DLP) projections achieving sub-25 um feature resolution.
- Dynamic Biomimetic Tissue Bioreactors:
- Continuous multichannel peristaltic perfusion circuits delivering oxygenated nutrient flow directly through lumen architectures.
- Programmable mechanical actuators delivering cyclical uniaxial or radial stretch to condition structural cells.
Sources 1 · 0 independent · 1 producer sites
Producers' own sites 1
- www.swissbiotech.org producer checked 2026-11-22